| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Tracheloside promotes wound healing through the phosphorylation of ERK1/2 (p-ERK1/2). [1]
|
|---|---|
| ln Vitro |
Tracheloside increased the proliferation of HaCaT human keratinocyte cells in a dose-dependent manner. At a concentration of 10 μg/ml, HaCaT cells grew over 45.58% more compared to the control (vehicle control) based on an MTT cell proliferation assay after 48 hours of treatment. [1]
An in vitro scratch assay (wound healing assay) showed that Tracheloside treatment (concentrations not specified in the result text, but methods used 1, 5, 10 μg/ml) resulted in more than 2-fold increased healing activity after 24 hours of treatment compared with the control. This activity was superior to that of allantoin (positive control), which showed a 1.2-fold increase after 24 hours. [1] Western blot analysis revealed that Tracheloside induced the phosphorylation of ERK1/2 (p-ERK1/2) in a dose-dependent manner (tested at concentrations 0, 1, 5, 10 μg/ml, as indicated in Figure 4), while the phosphorylation levels of p38 and JNK were not significantly affected. The densitometric analysis of p-ERK1/2 normalized with GAPDH showed an increase with Tracheloside treatment. [1] |
| Cell Assay |
Cell Proliferation Assay (MTT): HaCaT cells were seeded into 96-well plates at a density of 10^3 cells per well in DMEM. Serum-free medium containing various concentrations of Tracheloside (0, 1, 5, 10, 50, and 100 μg/ml) was added and incubated for 48 hours. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in PBS was added to each well at a final concentration of 0.5 mg/ml, followed by incubation for 3 hours at 37°C. The medium was then removed, and cells were suspended in DMSO for 10 minutes. Cell proliferation was calculated from optical density (OD540) values measured using a microplate reader and reported as a percentage of the vehicle control. [1]
In Vitro Wound Healing (Scratch) Assay: HaCaT cells were seeded into 6-well plates and cultured to near-confluent monolayers. A linear vertical and horizontal wound was generated in the monolayer with a sterile plastic pipette tip (20-200 μl). Cellular debris was removed by washing with phosphate-buffered saline (PBS). Serum-free medium with various concentrations of Tracheloside (1, 5, and 10 μg/ml) was added in triplicate and incubated for 24 hours at 37°C in a 5% CO2 atmosphere. Images of the scratched areas were photographed at 0 and 24 hours post-treatment. The percentage of scratch closure at each dose point relative to the control was calculated using an imaging system. The experiments were repeated three independent times. [1] Western Blot Analysis: Protein was extracted with RIPA buffer and quantified with Bradford reagent. Protein samples with equal amounts (25 μg) were separated by 8-10% SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% bovine serum albumin (BSA) and then incubated with a 1:2000 dilution of primary antibodies (p38α, p-p38, ERK1/2, JNK, p-JNK, and GAPDH; p-ERK1/2) overnight at 4°C. The membranes were washed with TBST and incubated with a secondary horseradish-peroxidase-conjugated antibody for 1 hour at room temperature. The membranes were developed using enhanced ECL on an imaging system. Each experiment was repeated at least twice for consistency. [1] |
| References | |
| Additional Infomation |
Tracheloside is a glycoside and lignan that acts as a metabolite. It has been reported to exist in Asian trachelospermum, jasmine trachelospermum, and other organisms with relevant data.
Tracheloside is a plant lignan that promotes wound healing by enhancing keratinocyte proliferation and migration. The wound healing activity of Tracheloside occurs through the phosphorylation of ERK1/2, which regulates cyclin D1 and controls cell proliferation. Based on the research results, Tracheloside could be recommended as a lead compound related to wound healing and skin proliferation. It is a good candidate to promote wound healing and could be developed as a therapeutic agent for wound treatment or used as a leading compound with higher activity. In vivo testing and experiments with epidermal tissue were not performed in this study. [1] |
| Molecular Formula |
C27H34O12
|
|---|---|
| Molecular Weight |
550.5517
|
| Exact Mass |
550.205
|
| CAS # |
33464-71-0
|
| PubChem CID |
169511
|
| Appearance |
White to off-white solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
769.8±60.0 °C at 760 mmHg
|
| Melting Point |
167-170℃
|
| Flash Point |
253.8±26.4 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.618
|
| LogP |
-0.54
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
39
|
| Complexity |
799
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O1C([C@](C([H])([H])C2C([H])=C([H])C(=C(C=2[H])OC([H])([H])[H])O[C@@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O2)O[H])O[H])O[H])([C@@]([H])(C([H])([H])C2C([H])=C([H])C(=C(C=2[H])OC([H])([H])[H])OC([H])([H])[H])C1([H])[H])O[H])=O
|
| InChi Key |
LWYAMIUSVGPFKS-CGLYQLBNSA-N
|
| InChi Code |
InChI=1S/C27H34O12/c1-34-17-6-4-14(9-19(17)35-2)8-16-13-37-26(32)27(16,33)11-15-5-7-18(20(10-15)36-3)38-25-24(31)23(30)22(29)21(12-28)39-25/h4-7,9-10,16,21-25,28-31,33H,8,11-13H2,1-3H3/t16-,21+,22+,23-,24+,25+,27-/m0/s1
|
| Chemical Name |
(3S,4S)-4-[(3,4-dimethoxyphenyl)methyl]-3-hydroxy-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl]oxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~181.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8164 mL | 9.0818 mL | 18.1637 mL | |
| 5 mM | 0.3633 mL | 1.8164 mL | 3.6327 mL | |
| 10 mM | 0.1816 mL | 0.9082 mL | 1.8164 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
